新的间皮瘤药物开始试验

Verismo Therapeutics announced that is has received clearance of its new drug for ovarian cancer, cholangiocarcinoma, and, mesothelioma from the U.S. Food and Drug Administration (FDA) to initiate a first-in-human Phase 1 clinical trial of SynKIR-110.

首次人体试验即将开始。他们将“解决几个医疗需求未得到满足的领域。 ” 卵巢癌的五年生存率为 49.7%，胆管癌为 30%，间皮瘤为 10%。

FDA 对新药的批准代表了间皮瘤治疗和创新研究的新进展。

Verismo 计划于 2023 年第一季度开始在最初的临床地点宾夕法尼亚大学医院招募患者。